FDA
-
-
-
-
-
-
-
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
-
-
-
-
-
-
-
BrainStorm raises $1 million in private placement at premium pricing
-
-
-
-
-
-
-
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
-
-
-
-
-
-
-
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS
-
-
-
-
-
-
-
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS
-
-
-
-
-
-
-
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
-
-
-
-
-
-
-
Brainstorm Cell Therapeutics (BCLI) Regains Nasdaq Compliance
-
329,957 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

